Dr. Chen has 30+ years of broad experience in biomedical research, biologics R&D, and corporate operations as an entrepreneur. Before establishing Biosion, Dr. Chen served as Senior Director of Monoclonal Antibody Operations at SDIX, Inc., where he led a team responsible for innovative antibody discovery services for leading biotech and pharmaceutical companies. Dr. Chen joined SDIX from Abbott Laboratories (now AbbVie), where he made critical contributions to several innovative biologic programs including ABT165 (now in Phase-II). Prior to AbbVie, he was responsible for developing innovative antibody therapeutics to novel targets at Lexicon Pharmaceuticals. Dr. Chen owns 20+ global patents of innovative antibodies; some of them are currently in different stages from preclinical to phase-II clinical studies.

Dr. Chen received his Ph.D. degree in Molecular Medicine from the University of Texas Health Science Center at San Antonio.